Selective inhibition of hepatitis B virus internalization by oxysterol derivatives

Given that the current approved anti-hepatitis B virus (HBV) drugs suppress virus replication and improve hepatitis but cannot eliminate HBV from infected patients, new anti-HBV agents with different mode of action are urgently needed. In this study, we identified a semi-synthetic oxysterol, Oxy185,...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical and biophysical research communications 2023-10, Vol.675, p.139-145
Main Authors: Oshima, Mizuki, Stappenbeck, Frank, Ohashi, Hirofumi, Iwamoto, Masashi, Fukano, Kento, Kusunoki, Atsuto, Zheng, Xin, Wang, Feng, Morishita, Ryo, Aizaki, Hideki, Suzuki, Ryosuke, Muramatsu, Masamichi, Kuramochi, Kouji, Sureau, Camille, Parhami, Farhad, Watashi, Koichi
Format: Article
Language:English
Subjects:
Antiviral
Entry
HBV
HDV
NTCP
Oxysterol
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Given that the current approved anti-hepatitis B virus (HBV) drugs suppress virus replication and improve hepatitis but cannot eliminate HBV from infected patients, new anti-HBV agents with different mode of action are urgently needed. In this study, we identified a semi-synthetic oxysterol, Oxy185, that can prevent HBV infection in a HepG2-based cell line and primary human hepatocytes. Mechanistically, Oxy185 inhibited the internalization of HBV into cells without affecting virus attachment or replication. We also found that Oxy185 interacted with an HBV entry receptor, sodium taurocholate cotransporting polypeptide (NTCP), and inhibited the oligomerization of NTCP to reduce the efficiency of HBV internalization. Consistent with this mechanism, Oxy185 also inhibited the hepatitis D virus infection, which relies on NTCP-dependent internalization, but not hepatitis A virus infection, and displayed pan-genotypic anti-HBV activity. Following oral administration in mice, Oxy185 showed sustained accumulation in the livers of the mice, along with a favorable liver-to-plasma ratio. Thus, Oxy185 is expected to serve as a useful tool compound in proof-of-principle studies for HBV entry inhibitors with this novel mode of action. •Oxy185 inhibited HBV infection through reducing viral internalization.•Oxy185 directly interacted with an HBV receptor, NTCP.•Oxy185 inhibited the oligomerization of NTCP.•Oxy185 showed broad antiviral activity to multiple HBV isolates.•Oxy185 showed preferable pharmacokinetics, accumulated in liver of oral treated mice.
ISSN:0006-291X
1090-2104
DOI:10.1016/j.bbrc.2023.07.014